Email this page: News Release
Intellipharmaceutics Intends to Accelerate its Rexista(TM) Oxycodone XR Development Program on the Basis of Positive Feedback from the FDA
To (email address):
Separate multiple addresses with commas. Maximum 200 characters.
Your email address:
These email addresses will be used to email the page on your behalf and will not be used by Intellipharmaceutics for any marketing purposes.
Add a comment:
Link to page
Type in number:
This helps Intellipharmaceutics prevent automated submissions.